Genpact's deep domain knowledge and data
expertise enables embecta's vision to make a meaningful impact in
the healthcare sector
NEW
YORK, July 29, 2024 /PRNewswire/ --
Genpact (NYSE: G), a global professional services and
solutions firm delivering outcomes that shape the future, has been
working with embecta (Nasdaq: EMBC), a global
diabetes care company, to support its spin-off from Becton Dickinson and Company (BD) and subsequent
evolution as an independent leader in the diabetes technology
market.
"Genpact's deep expertise in the life sciences and healthcare
sectors enables us to leverage extensive knowledge alongside our
capabilities in data, technology, and AI. This combination allows
us to drive positive outcomes and provide innovative solutions
tailored to our clients' needs," said Balkrishan "BK" Kalra,
President and CEO, Genpact. "Together, we are dedicated to
realizing embecta's mission - to develop and provide solutions that
make life better for people living with diabetes – and furthering
Genpact's purpose: the relentless pursuit of a world that works
better for people."
Genpact initially supported embecta's spin-off from BD and over
time, the partnership has evolved to modernize embecta's
operations. More specifically, Genpact supported the implementation
of a robust ERP and launched an operating model with standardized
global processes to meet the needs of a newly formed medical device
company. Additionally, Genpact established end-to-end HR, finance,
and procurement processes. This provided uninterrupted customer
support and supply chain stability enabling embecta to continue
providing insulin injection devices to 30 million people in more
than 100 countries without interruption.
"From the beginning, our relationship was rooted in shared
values and a commitment to mutual success," said Devdatt (Dev)
Kurdikar, President and Chief Executive Officer, embecta. "Our
seamless collaboration resulted in the successful transition of
embecta to an independent entity, ensuring a continuous flow of
goods and working capital, maintaining supply chain continuity, and
providing critical support for our customers and the people they
serve."
Visit here for more information about Genpact's work in the
healthcare industry.
About Genpact
Genpact (NYSE: G) is a global professional services and
solutions firm delivering outcomes that shape the future. Our
125,000+ people across 30+ countries are driven by our innate
curiosity, entrepreneurial agility, and desire to create lasting
value for clients. Powered by our purpose – the relentless pursuit
of a world that works better for people – we serve and transform
leading enterprises, including the Fortune Global 500, with our
deep business and industry knowledge, digital operations services,
and expertise in data, technology, and AI.
Get to know us at genpact.com and
on LinkedIn, X, YouTube,
and Facebook.
MEDIA CONTACT:
Siya Belliappa
Genpact Media Relations
+1
7185619843
Siya.belliappa@genpact.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/genpact-supports-embectas-spin-off-into-an-independent-diabetes-care-company-302208349.html
SOURCE Genpact Ltd.